- Intestinal epithelial barrier – enteric nervous system – gut brain axis disease/MICI (CIBD) – TENS
- Intestinal epithelial barrier – developmental origin of chronic pathologies – PhAN
- Blood-brain barrier – neuroinflammation – multiple sclerosis – PhIND
- Skin epithelial barrier (pathologies such as atopic dermatitis, allergy) – BIA
- Cutaneous epithelial barrier (psoriasis-type pathology)
- Pulmonary epithelial barrier asthma, allergy – IT
- Endothelial barrier (metabolic syndrome and sleep apnea) – SOPAM
- Intestinal epithelial barrier – hepato-gastroenterology – oral microbiota – toxicology – Numecan
- Pesticide study – BRGM
EXPERTISE
Organ barrier
Therapeutic targeting of microbiota or organ barriers
Data analysis
- Computational analysis, antibiotic resistance – MiHAR
- Comparative genomics, systems biology – LS2N
Technological analysis platforms
- PF In vivo/in vitro digestive model – digestive permeability study – TENS
- PF In vivo/in vitro pulmonary epithelial barrier asthma allergy model – IT
- PF Paediatric exploration – PhAN
- PF Cellular analysis – SOPAM
- PF Preclinical liver tissue image analysis, non-invasive liver disease diagnostic tests – HIFIH
- PF P2R recombinant protein – CRCINA
- PF PREMS / BBB permeability/PF animal and human imaging – PhIND
- PF RNA-Seq based transcriptome analysis – Biogenouest
- PF microbiota analysis – Biofortis
RELATED PROJECTS
Mibiogate project partners are also involved in preclinical or clinical projects and in the elaboration of new projects thanks to the development of the Mibiogate network. Mibiogate encourages communication and exchange between the players in the Greater western region, through the organization of scientific seminars as well as the development and highlighting of expertise through research projects and communication/promotion initiatives. The following are examples of structuring projects resulting from or related to Mibiogate on the themes: microbiota/biological barriers/chronic diseases.
POCA Projects
Category :
Clinical
Abstract :
Inflammation of the intestinal reservoir (pouchitis) in patients with ulcerative colitis (UC) involves a deregulated inflammatory response to intestinal bacteria. Modification of this microbiota by a faecal microbiota transplantation (FMT) could modulate this response and prevent a possible relapse.
Main objective :
Compare chronic pouchitis time to relapse after faecal transplantation versus fictive transplantation in patients with ileal pouch-anal anastomosis in the context of ulcerative colitis.
Secondary objectives :
1. Efficacy of FMT on relapse rate at 24 weeks and 52 weeks.
2. Initiation of alternative treatment within 52 weeks after FMT.
3. FMT safety in the event of pouchitis.
4. Faecal microbiota modification in patients with recurrent chronic pouchitis in remission after antibiotic therapy and at 8 weeks of FMT from a healthy donor
5. Evolution of disability.
Two biocollections will be established and centralised at Nantes University Hospital. One will collect donor faeces samples and the other patient biopsies and faeces samples.
Abstract:
Results or projected end date :
first patient enrolment in May 2018
Partners involved :
IMAD
CHU de Nantes
Project lead contact :
Dr Caroline Trang-Poisson
Funding source :
PHRC
PREGRALL Project
Category :
Clinical
Abstract :
Study aimed at evaluating the efficacy of antenatal maternal supplementation with GOS/Inulin prebiotics on the occurrence of atopic dermatitis in one-year old infants with atopic risk.
Results or projected end date :
Study in progress/end date: January 2021
Partners involved :
INRA BIA (allergy)
University Hospital Nantes (patient cohort)
Project lead contact :
Marie Bodinier (INRA)
Sébastien Barbarot (CHU Nantes)
Source de financement :
PHRC inter-regional
Promotion/Publication :
Publication : https://doi.org/10.1016/j.annder.2017.09.297
This clinical study is associated with an ancillary study, CIMMAP, funded by the ANR (Collaborative Research Project: Translational Health Research). CIMMAP, coordinated by Marie Bodinier (UR1268 BIA, Allergy team), explores the perinatal period in children at risk of allergy by focusing on the development of the immune system (IS) and microbiota; the effects of breast milk on these parameters; the modulation of the infantile IS by maternal microbiota and its derivatives; the effects of prebiotics on the IS/microbiota/milk. A preclinical model shall specify the mechanisms at an organic level. CIMMAP will assist in refining the pathophysiology of allergies and in identifying the risk and tolerance biomarkers.
